A recent press release by Boston Scientific announced the U.S. FDA approval of their ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS) System.
Editor's Note: This article originally appeared on Boston Scientific's website.
Boston Scientific Corporation (NYSE:BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment.1 This system, with the Vercise Cartesia™ Directional Lead, is designed to treat the symptoms of Parkinson's Disease (PD) by delivering precisely targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects.
An estimated ten million people worldwide are affected by Parkinson's disease, causing symptoms such as shaking or tremors, muscle stiffness, and slowness of movement.2 DBS therapy helps patients with Parkinson's disease control their symptoms and improve their quality of life. This FDA approval allows patients to undergo a full-body MRI1 while benefiting from the latest advances in DBS therapy including directional stimulation and a longer-lasting rechargeable battery. Click here to continue>>
News From Our Partners